OBJECTIVE -Studies examining vasodilatory responses to acetylcholine (ACh) and its derivatives have been conflicting. Enhanced activation of the cyclo-oxygenase pathway and increased availability of vasodilatory prostanoids may occur in type 1 diabetes, and this may compensate for the observed reduction in nitric oxide (NO) activity. We examined the role of cyclo-oxygenase inhibition on vasodilatory responses in 12 healthy normotensive type 1 diabetic adults and 12 nondiabetic control subjects of similar age, sex, and BMI.
V ascular disease is the principal cause of death and disability in patients with diabetes (1) , and endothelial dysfunction has been implicated in its pathogenesis (2) (3) (4) . The normal vascular endothelium plays an important role in maintaining vessel wall homeostasis, synthesizing substances such as prostacyclin and nitric oxide (NO) which modulate vascular tone, prevent thrombosis, and influence smoothmuscle growth (5) . Intra-arterial infusion of acetylcholine (ACh) has been widely used to examine endothelial function, because it is thought to stimulate a vasodilatory response mediated, at least in part, through the L-arginine-NO pathway. Inhibition of NO synthesis, however, does not completely abolish vasodilation, indicating that alternative pathways may be involved (6) .
Studies that have examined responses to ACh or the muscarinic agonists in type 1 diabetes have been conflicting (7) (8) (9) (10) , despite the apparent attenuated NO activity that has been observed in diabetes (9, 10) . There is evidence that vasodilatory prostanoids may be important in determining responses to ACh in both diabetic (4) and nondiabetic subjects (11, 12) , their effects being mediated through an increase in cyclic AMP. We hypothesized that increased prostaglandin-mediated vasodilation might compensate for decreased activity of the NO pathway in type 1 diabetes. We therefore examined responses to ACh in the forearm vasculature of patients with type 1 diabetes and a nondiabetic control group before and after the intraarterial infusion of indomethacin.
RESEARCH DESIGN AND METHODS -
We recruited 12 normoalbuminuric type 1 diabetic subjects without evidence of microvascular complications and with a minimum 5 years' duration of diabetes from the diabetes clinics at Queen Alexandra Hospital, Portsmouth, U.K. In addition, a control group of 12 healthy volunteers of similar age and sex were recruited from hospital staff. Subjects in each group were normotensive normolipidemic lifelong nonsmokers, not taking concurrent medication and with no family history of coronary artery disease. Subjects had no evidence of coronary artery or macrovascular disease based on a careful history, physical examination, and a normal 12-lead electrocardiogram. Approval for the study was obtained from Portsmouth Hospital' s National Health Services Trust ethical committee. Informed written consent was obtained from all subjects. Subjects abstained from tobacco and alcoholic and caffeine-containing beverages during the night before the study. They were studied in the afternoon and asked to keep to their usual dietary and insulin regimes. Blood pressure was recorded twice after the subjects had been seated for 5 min. At the onset of each study, a blood sample was taken for HbA 1c , plasma glucose, total cholesterol, and triglyceride concentrations. In addition, a mean albumin:creatinine ratio was calculated from the analysis of two early-morning urine samples collected from subjects on successive days before the study. HbA 1c was measured by high-performance liquid chromatography (Menarini, Wokingham, U.K.) (intra-assay coefficient of variation [CV] 1.5%) and plasma glucose by a glucose oxidase technique (DAX 96; Bayer Diagnostics, Newbury, U.K.) (CV 3%). Plasma total cholesterol concentration was measured by esterase and oxidase conversion (DAX 72; Bayer) (CV 1.9%) and plasma triglyceride concentration by enzymatic determination (DAX 72) (CV 1.7%). Urine albumin concentration was measured by radioimmunoassay (13) (CV Ͻ9%). Urinary creatinine concentration was measured by an end-point Jaffe reaction (CV Ͻ6%). All blood pressures were recorded in the noninfused arms of supine subjects by sphygmomanometry before blood flow was measured. Capillary blood glucose measurements were taken by finger-prick testing from the noninfused fingers of subjects (Glucometer 4 meter; Bayer) before ACh infusion and before and after indomethacin.
Forearm blood flow studies were carried out with subjects in a supine position and in an air-conditioned room at room temperature (24°C). Forearm blood flow was examined in both arms using bilateral venous occlusion plethysmography using mercury-filled silastic strain-gauge bands (14) that were electrically calibrated (15) . (The strain-gauge method is a standard technique that measures percentage change in arm circumference and arm volume [16] .) During measurements, the hands were excluded from the circulation by inflation of wrist cuffs to 200 mmHg or 20 mm more than systolic pressure. Every 15 s, upper-arm collecting cuffs were inflated to 40 mmHg for 10 s and then deflated for the remaining 5 s to allow venous emptying. Blood flow was recorded during the period of inflation. A 27-gauge unmounted steel needle (Cooper' s Needle Works, Birmingham, U.K.) sealed with dental wax to an epidural cannula (Portex, Hythe, U.K.) was inserted into the patients' left brachial artery under local anesthesia (Ͻ1 ml of 1% lignocaine) for the purpose of drug infusion. Saline was then infused for 15 min at 1 ml/min by means of a constantrate infusion pump (IVAC P3000; IVAC, Basingstoke, U.K.). Forearm blood flow was measured at baseline after the infusion of saline and after incremental doses of both nitroprusside (David Bull, Victoria, Australia) (1, 3, and 10 µg/min), an endothelium-independent vasodilator, and ACh (CibaVision, Southampton, U.K.) (7.5, 15, and 30 µg/min), an endotheliumdependent vasodilator. Each drug was dissolved in 0.9% sodium chloride and infused at a constant rate for 6 min at each dose. Nitroprusside and ACh infusions were separated by an infusion of saline (Ն6 min), and forearm blood flow was measured for the final 3 min of saline infusion t o c o n f i r m a re t u r n t o b a s e l i n e . Indomethacin (Merck Sharp & Dohme, Hoddesdon, U.K.), a cyclo-oxygenase inhibitor, was then infused over 20 min (0.3 mg/100 ml forearm tissue). Forearm blood flow was reexamined at baseline and after a repeat infusion of ACh (7.5, 15, and 30 µg/min). The mean of the final five measurements of each recording period was used for analysis. Blood flow was expressed as milliliters per minute per 100 ml of forearm tissue (14) .
Statistical analysis
Results are expressed as means ± SEM. Physical and biochemical variables were compared by unpaired t tests. For hemodynamic responses to drugs, areas under the curve (AUCs) were calculated using the trapezoidal method. Group comparisons were carried out by repeated-measures analysis of variance. The statistical package NCSS 6.0 (NCSS, Kaysville, UT) was used. A P value of Ͻ0.05 was considered to indicate statistical significance. Change in absolute forearm blood flow after indomethacin was expressed as a percentage reduction in blood flow.
RESULTS -
The subject characteristics are given in Table 1 . None had clinical evidence of microalbuminuria or retinopathy. Plasma glucose concentration in the diabetic patients was similar before and after indomethacin infusion (10.7 ± 2.3 vs. 9.5 ± 1.3 mmol/l, respectively; P = 0.34).
At baseline, forearm blood flow in diabetic and control subjects was similar (Table 2) . After nitroprusside and ACh, the increase in forearm blood flow was similar in diabetic and control subjects ( Table 2) .
After indomethacin, the vasodilatory responses to ACh were significantly reduced in the diabetic group (by 22.84 ± 5.18, 25.77 ± 5.14, and 23.45 ± 4.60% for 7.5, 15, and 30 µg/min doses, respectively; P = 0.03, P = 0.03, and P = 0.04, respectively). After indomethacin, the vasodilatory responses to ACh in the control group were significantly reduced at 7.5-and 30-µg doses with a trend toward significance at the 15-µg dose (by 19.14 ± 5.49, 11.93 ± 5.46, and 10.27 ± 2.05%, respectively; P = 0.04, P = 0.06, and P = 0.04, respectively). The reduction in forearm blood flow response to ACh after indomethacin infusion was greater in diabetic compared with control subjects (25.30 ± 4.90 vs. 11.23 ± 5.45%, respectively) (Fig. 1) . 
Prostaglandin-mediated vasodilation in type 1 diabetes
CONCLUSIONS -This is the first study to examine the role of prostaglandinmediated vasodilation in response to ACh infusion in type 1 diabetic patients. We have confirmed that vasodilatory prostanoids are important in determining the response to ACh in both diabetic (4) and nondiabetic subjects (11, 12) . We have also demonstrated that, in the absence of pretreatment with a cyclo-oxygenase inhibitor, endothelium-dependent vasodilation is not impaired in type 1 diabetic patients who have no evidence of additional macrovascular risk. This is in agreement with the work of Smits et al. (7) . After indomethacin, an inhibitor of the cyclo-oxygenase pathway, there was a reduction in vasodilatory responses to all doses of ACh in both groups. Importantly, the effects on cyclooxygenase inhibition were greater in the diabetic compared with the control group. The rationale for this study was based on several previous observations. Infusion of N G -monomethyl-L-arginine (L-NMMA), an NO synthase inhibitor, reduced resting forearm blood flow to a lesser extent in diabetic patients with recent onset of diabetes who were likely to have normal urinary albumin excretion (17) compared with nondiabetic control subjects (9) . This attenuated response to L-NMMA was confirmed in a further study of microalbuminuric diabetic patients at baseline and after the infusion of carbachol, which, like ACh, stimulates NO release from the endothelium (10). Despite these findings, studies examining endothelial function in type 1 diabetes using ACh or derivatives have been conflicting. Vasodilatory responses to ACh (9) and methacholine (7) were reported as being unchanged in a group of type 1 diabetic patients compared with a nondiabetic control group. Conversely, Johnstone et al. (8) showed an impaired response to ACh in type 1 diabetes. In this latter study, however, subjects were pretreated with 325 mg/day of aspirin for 3 days to exclude the potential confounding effects of vasoactive prostaglandins. This raised the possibility that, in type 1 diabetes, endotheliumdependent vasodilatory response to ACh is more dependent on prostaglandin-mediated relaxation, thereby compensating for the observed reduction in NO activity. This would be consistent with the finding that hyperglycemia stimulates cyclo-oxygenase activity, the rate-limiting enzyme for prostaglandin formation (18) .
The reduction in blood flow after indomethacin was greater in diabetic patients compared with control subjects, consistent with the idea that increased prostaglandin-mediated vasodilation may be compensating for attenuated responses to NO in diabetic subjects. The effects of indomethacin are mediated through cyclooxygenase inhibition (19) . A dose of 0.3 mg/100 ml has been previously shown to abolish forearm prostaglandin release (20) . These findings may partly explain the conflicting reports of endothelial dysfunction in type 1 diabetes. Our findings are unlikely to be a result of a direct effect of hyperglycemia on endothelial function, because blood glucose concentration before and after treatment with indomethacin was similar. In addition, there is evidence that vasodilatory responses to ACh are not directly affected by moderate hyperglycemia in the acute setting (21) . Recent studies have suggested that insulin could enhance the production of NO and endothelin-1. This might contribute to changes in cyclo-oxygenase activity (22) and could be a confounding factor. We chose to study our patients under typical physiological conditions rather than artificially clamping to control glucose or insulin concentration to avoid creating an artificial rather than physiological study environment. 
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Endothelium-dependent vascular function has been examined using other techniques in animal models of diabetes and in diabetic patients. Those investigating isolated conduit arteries from diabetic animals have shown blunting of the normal vasodilatory response to ACh. As discussed above, however, there are a significant number of studies that dispute these findings (see the article by Poston and Taylor [4] for review). Reports examining ACh in vivo using other methods have been conflicting (4). Flowmediated dilation (measured by high-resolution ultrasound) is an alternative approach used to examine endothelium-dependent function and was found to be reduced in the forearm conduit vessels of a heterogeneous group of young diabetic patients with poor glycemic control compared with a nondiabetic control group (23) . The absence of consistent findings between studies may reflect the lack of pretreatment with inhibitors of the cyclo-oxygenase pathway, thus confounding the results. Other possibilities include intrinsic differences in the vascular beds under observation, differences in experimental conditions, or the heterogeneous characteristics of the study subjects. Our study involved patients with a mean duration of diabetes of 13 years, whereas previous studies have examined patients with a lesser disease duration (8, 9) . These patients will have had reduced exposure to chronic hyperglycemia and the potential for development of advanced glycation end products that have been implicated in diabetic vascular dysfunction (24) . We did not extensively screen our patients for micro-or macrovascular disease. However, our study patients are chosen deliberately to be representative of the diabetic population.
Our findings apply to normoalbuminuric type 1 subjects, but whether similar reductions in ACh-mediated vasodilation after indomethacin occur in diabetic subjects with microalbuminuria, an established risk factor for the development of coronary artery disease, is unknown and deserves further study. Differences in endothelial function between microalbuminuric and normoalbuminuric diabetic subjects have been reported (10) , although these findings have not been confirmed by other investigators (23) . Given the significantly attenuated vasodilatory responses to ACh after indomethacin infusion, this study demonstrates the importance of vasodilatory prostaglandins in determining regulatory tone in type 1 diabetes. Our findings also suggest that the reduction in NO activity observed in some previous studies may have been underestimated. Further investigation is required into the mechanisms of prostaglandin-mediated vasodilation in type 1 diabetes.
